NCT00408395

Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children

A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 281 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 6 Months – 35 Months
• Healthy volunteers: Accepted

Summary

This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children.

Detailed description

A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a commercially available influenza vaccine versus Two 0.25 mL Intramuscular Doses of a commercially available influenza vaccine in Healthy Children

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Influenza vaccine	Seasonal Influenza Vaccine

Timeline

• Start date: 2006-11-01
• Primary completion: 2007-08-01
• Completion: 2007-08-01
• First posted: 2006-12-06
• Last updated: 2016-12-01

Locations

1 site across 1 country: Finland